Design Therapeutics
DSGN
95 hedge funds and large institutions have $260M invested in Design Therapeutics in 2025 Q3 according to their latest regulatory filings, with 14 funds opening new positions, 17 increasing their positions, 38 reducing their positions, and 11 closing their positions.
800% more call options, than puts
Call options by funds: $9K | Put options by funds: $1K
123% more capital invested
Capital invested by funds: $116M → $260M (+$143M)
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
27% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 11
3% more funds holding
Funds holding: 92 → 95 (+3)
0.26% less ownership
Funds ownership: 60.83% → 60.57% (-0.26%)
55% less repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 38
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$7.68M |
| 2 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$2.38M |
| 3 |
Jane Street
New York
|
+$435K |
| 4 |
Millennium Management
New York
|
+$345K |
| 5 |
DAM
DLD Asset Management
New York
|
+$250K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LGM
Logos Global Management
San Francisco,
California
|
-$2.82M |
| 2 |
BlackRock
New York
|
-$1.76M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$1.44M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.05M |
| 5 |
WP
Woodline Partners
San Francisco,
California
|
-$826K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
101
Los Angeles Capital Management
Los Angeles,
California
| – | -$42.9K | -12,735 | Closed |
|
102
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
| – | -$40.3K | -11,955 | Closed |
|
|
PD
103
Point72 (DIFC)
Dubai,
United Arab Emirates
| – | -$66 | -20 | Closed |
|
|
BIG
104
Brooklyn Investment Group
Brooklyn,
New York
| – | -$65 | -19 | Closed |
|
105
Osaic Holdings
Scottsdale,
Arizona
| – | -$34 | -10 | Closed |
|
DSGN Hedge Fund Activity: Q3 2025 in Review
95 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in Design Therapeutics (DSGN) for Q3 2025, worth a combined $260M — up 123% from $116M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new DSGN positions and 11 closed out — a net gain of 3 holders — while 17 added to existing stakes and 38 trimmed.
The largest buyer was Point72 Asset Management, adding an estimated $7.68M. The largest seller was Logos Global Management, cutting an estimated $2.82M.
- 95 institutional investors held Design Therapeutics (DSGN) as of Q3 2025, up from 92 in Q2 2025.
- Funds reported $260M of Design Therapeutics stock for Q3 2025, up 123% quarter-over-quarter.
- 14 funds opened new Design Therapeutics positions in Q3 2025 and 11 closed out, a net change of +3 holders.
- The largest Design Therapeutics buyer in Q3 2025 was Point72 Asset Management, an estimated $7.68M added.
- The largest Design Therapeutics seller in Q3 2025 was Logos Global Management, an estimated $2.82M sold.
Based on aggregated 13F filings for Q3 2025.